TABLE 4.
Additional CAP patient characteristics and secondary outcome dataa
| Characteristic | Total (n = 220) |
|---|---|
| CAP severity—n (%) | |
| Non-severe | 212 (96.4) |
| Severe | 8 (3.6) |
| Patients initially receiving broad-spectrum therapy—n (%) | 71 (32.3) |
| De-escalation within 72 hours from initiation of broad-spectrum initial therapy—n (% of patients initially receiving broad-spectrum therapy) | |
| Yes | 29 (40.8) |
| No | 42 (59.2) |
| Duration of antibiotic therapy—days | |
| Duration of IV therapy—median (IQR) | 4 (2–4) |
| Duration of PO therapy—median (IQR) | 4 (2–4) |
| Total duration of therapy—median (IQR) | 7 (6–9) |
| Initial antibiotic therapy—n (%) | |
| Ceftriaxone | 1 (0.5) |
| Ceftriaxone + azithromycin | 105 (47.7) |
| Ceftriaxone + doxycycline | 16 (7.3) |
| Ceftriaxone + moxifloxacin | 2 (0.9) |
| Doxycycline | 1 (0.5) |
| Moxifloxacin | 24 (10.9) |
| Piperacillin/tazobactam | 1 (0.5) |
| Piperacillin/tazobactam + moxifloxacin | 1 (0.5) |
| Vancomycin + azithromycin | 1 (0.5) |
| Vancomycin + ceftriaxone + azithromycin | 5 (2.3) |
| Vancomycin + ceftriaxone + moxifloxacin | 1 (0.5) |
| Vancomycin + aztreonam + azithromycin | 1 (0.5) |
| Vancomycin + aztreonam + moxifloxacin | 1 (0.5) |
| Vancomycin + cefepime | 4 (1.8) |
| Vancomycin + cefepime + azithromycin | 1 (0.5) |
| Vancomycin + cefepime + moxifloxacin | 1 (0.5) |
| Vancomycin + meropenem | 1 (0.5) |
| Vancomycin + piperacillin/tazobactam | 22 (10.0) |
| Vancomycin + piperacillin/tazobactam + azithromycin | 9 (4.1) |
| Vancomycin + piperacillin/tazobactam + ciprofloxacin | 8 (3.6) |
| Vancomycin + piperacillin/tazobactam + ciprofloxacin + doxycycline | 1 (0.5) |
| Vancomycin + piperacillin/tazobactam + doxycycline | 6 (2.7) |
| Vancomycin + piperacillin/tazobactam + moxifloxacin | 7 (3.2) |
a
Abbreviations: IQR, interquartile range; PO, by mouth.